Immunovant faces high R&D costs, limited cash runway, and unproven clinical edge despite pipeline progress and deeper IgG ...

Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Detailed price information for J B Hunt Transport (JBHT-Q) from The Globe and Mail including charting and trades.

— We have everything you need: full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...

On Friday, H.C. Wainwright adjusted its price target on shares of Immunovant (NASDAQ: IMVT), reducing it to $35.00 from the previous target of $54.00, while maintaining a Buy rating on the company’s ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Immunovant, Inc. IMVT reported fourth-quarter fiscal 2025 net loss of 64 cents per share, narrower than the Zacks Consensus Estimate of a loss of 72 cents. The reported figure is wider than the ...